Article
Oncology
Hongen Kang, Xiuli Zhu, Ying Cui, Zhuang Xiong, Wenting Zong, Yiming Bao, Peilin Jia
Summary: This study aimed to find biomarkers that can predict immune checkpoint blockade (ICB) responses. By analyzing 29 published datasets and 39 sets of biomarkers, the researchers found that most biomarkers performed poorly in different datasets. Two scores (TIDE and CYT) showed competitive performance in predicting ICB responses, and two others (PASS-ON and EIGS_ssGSEA) were associated with the best clinical outcomes. They also developed ICB-Portal to provide resources and computational methods for ICB-related research.
Article
Immunology
Alexander Piening, Emily Ebert, Niloufar Khojandi, Elise Alspach, Ryan M. Teague
Summary: This study aims to investigate the impact of immune checkpoint blockade (ICB) on immune responses in cancer patients previously vaccinated against COVID-19. The study found that ICB treatment does not significantly enhance antibody titers and T cell responses in vaccinated individuals. These results provide evidence supporting the clinical safety and efficacy of COVID-19 vaccination in patients receiving ICB.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Hua Zhu, Xinyao Hu, Shi Feng, Lijuan Gu, Zhihong Jian, Ning Zou, Xiaoxing Xiong
Summary: The study found that high expression of PIMREG in glioma is associated with poor prognosis. PIMREG is related to the infiltration of various immune cell types and is correlated with immune checkpoints and patients' responses to immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Hufei Wang, Zhi Li, Suwen Ou, Yanni Song, Kangjia Luo, Zilong Guan, Lei Zhao, Rui Huang, Shan Yu
Summary: This study integrated multiple CRC cohorts to construct tumor microenvironment subtypes and establish a TMEIG score system, which correlated with clinical outcomes and exhibited distinct immune statuses in CRC patients. Patients with low TMEIG scores were more likely to benefit from ICB therapy. Furthermore, five genes (SERPINE1, FABP4, SCG2, CALB2, and HOXC6) in the TMEIG score system were closely associated with tumorigenesis, immune cells, and ICB response indices. The study provided new insights into precision ICB therapy in CRC.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Article
Oncology
Evan Rosenbaum, Cristina R. Antonescu, Shaleigh Smith, Martina Bradic, Daniel Kashani, Allison L. Richards, Mark Donoghue, Ciara M. Kelly, Benjamin Nacev, Jason E. Chan, Ping Chi, Mark A. Dickson, Mary L. Keohan, Mrinal M. Gounder, Sujana Movva, Viswatej Avutu, Katherine Thornton, Ahmet Zehir, Anita S. Bowman, Samuel Singer, William Tap, Sandra D'Angelo
Summary: This study retrospectively evaluated the clinical and molecular characteristics of angiosarcoma patients treated with ICB therapy. The results showed that ICB therapy is effective in some angiosarcoma patients, particularly those with cutaneous angiosarcoma of the head and neck.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Medicine, Research & Experimental
Han Chu, Zheng Jin, Jia-nan Cheng, Qingzhu Jia, Bo Zhu, Haoyang Cai
Summary: In this study, the association among chromothripsis, anti-tumor immune responses, and responsiveness to immune checkpoint blockade (ICB) was investigated. It was found that tumors with chromothripsis had reduced cytotoxic immune infiltration and enhanced immunosuppression in the tumor microenvironment. Chromothripsis can be used as an independent predictor for the responsiveness to ICB.
Article
Oncology
Ming Zheng
Summary: This study demonstrates that the neutrophil-to-lymphocyte ratio (NLR) is a valuable indicator for predicting the outcomes of immune checkpoint blockade (ICB) treatment. An NLR range of 2.0 to 3.0 is associated with optimal treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Simona Pagliuca, Carmelo Gurnari, Keman Zhang, Tariq Kewan, Waled Bahaj, Minako Mori, Ishani Nautiyal, Marie Therese Rubio, Francesca Ferraro, Jaroslaw P. Maciejewski, Li Wang, Valeria Visconte
Summary: V-domain Ig suppressor of T-cell activation (VISTA) is a critical negative regulator of antitumor immune response. In this study, the researchers explored the role of VISTA in the generation of an immune escape environment in acute myeloid leukemia (AML) patients. They found that VISTA expression levels were correlated with AML cell differentiation, NPM1 mutations, and disease recurrence.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Nicolas Roussot, Julie Lecuelle, Lorraine Dalens, Caroline Truntzer, Francois Ghiringhelli
Summary: A novel crosstalk between immunogenic and oncometabolic pathways triggered by T cell-released interferon-gamma (IFN-gamma) has been identified. This study explores the relationship between genomic tumor FGF2 or FGF/FGF receptor (FGFR) amplification and immunotherapy response in patients with metastatic solid cancers. The results demonstrate that FGF2 genomic amplification is associated with shorter progression-free survival and overall survival in patients undergoing immune checkpoint blockade therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Chemistry, Multidisciplinary
Guiyuan Chen, Xiangxia Li, Rui Li, Kecheng Wu, Zhouhang Lei, Ruike Dai, Kyle Roche, Andrew Z. Wang, Yuanzeng Min
Summary: Researchers hypothesized that treating cancer cells with ultrahigh doses of chemotherapeutics in vitro could artificially enhance the immunogenicity, thereby improving chemoimmunotherapy.
Review
Chemistry, Multidisciplinary
Elham Masoumi, Sahar Tahaghoghi-Hajghorbani, Leila Jafarzadeh, Mohammad-Javad Sanaei, Atieh Pourbagheri-Sigaroodi, Davood Bashash
Summary: This review provides an overview of the current research status of immune checkpoint blockades in breast cancer and discusses the efficacy and limitations of ICB therapy in breast cancer treatment.
JOURNAL OF CONTROLLED RELEASE
(2021)
Review
Immunology
Mohammad Hossein Kazemi, Alireza Najafi, Jafar Karami, Foad Ghazizadeh, Hassan Yousefi, Reza Falak, Elahe Safari
Summary: Recent advancements in cancer immunotherapy, particularly immune checkpoint (IC) blockers, have shown promising results in clinical settings. Immunometabolism plays a crucial role in regulating immune responses, and dual targeting of ICs and metabolic pathways may help restore immune cells' antitumor activity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Jimmy A. Guo, Mohammed Alshalalfa, Daniel Y. Kim, Hannah I. Hoffman, Carina Shiau, Jennifer Su, William L. Hwang, Brandon A. Mahal
Summary: This study examined the association between mutations in 25 core DNA repair genes and immune checkpoint blockade outcomes in advanced cancer patients. The results showed that mutations in 7 DNA repair genes were significantly associated with improved overall survival in immune checkpoint blockade-treated patients and had significant interaction with treatment. The study suggests that these mutations could serve as a biomarker independent of cancer type.
Review
Immunology
Noah Earland, Wubing Zhang, Abul Usmani, Aishwarya Nene, Antonella Bacchiocchi, David Y. Chen, Mario Sznol, Ruth Halaban, Aadel A. Chaudhuri, Aaron M. Newman
Summary: Immune-related toxicities, also known as immune-related adverse events (irAEs), are common side effects in cancer patients treated with immune checkpoint inhibitors (ICIs). These side effects can range from mild to severe, leading to hospitalization, high-dose corticosteroid treatment, discontinuation of ICIs, and even death. Through recent research, we have identified two baseline features - elevated activated CD4 effector memory T-cell abundance and TCR diversity - in circulation that are associated with severe irAE development in advanced melanoma patients. This understanding provides a foundation for improving irAE prediction and prevention, ultimately reducing morbidity and mortality associated with ICIs.
IMMUNOLOGICAL REVIEWS
(2023)
Article
Oncology
Yuxuan Song, Yun Peng, Caipeng Qin, Yulong Wang, Wenbo Yang, Yiqing Du, Tao Xu
Summary: FGFR3 mutation may attenuate prognosis and response to immune checkpoint blockade (ICB) therapy in patients with metastatic urothelial carcinoma (UC), likely due to the immunosuppressive microenvironment caused by FGFR3 mutation.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)